Ivantis

Ivantis has developed the Hydrus™ Microstent, the world’s first “intracanalicular scaffold” for the treatment of primary open angle glaucoma (POAG).

The Hydrus procedure is designed to be less invasive than traditional glaucoma surgery and can be performed during cataract surgery using the same microsurgical incisions. Roughly the size of an eyelash, the Hydrus Microstent is made from a super-elastic, biocompatible alloy (nitinol®), which is a well-proven biomaterial used in over 1 million implants in a variety of medical devices to date.

Exit Date: 2022

Ivantis logo
Team

Venture Capital

Status

Divested

Geography

US

Financing Round

-

Segment

MedTech

Entry Date

2017

Key Figures

Divested

Status

2007

Creation Date

2017

Investment Date

Mérieux Participations 2

Fund Name

2022

Investment’s Exit Date

Key Contacts

Related companies